Cargando…
The Uro-oncology Patient and Vaccination Against SARS-CoV-2
As of April 13, 2021, 137 million cases of COVID-19 and 2.95 million deaths have been reported worldwide. On December 21, 2020, the Pfizer-BioNTech vaccine was approved for use in the European Union, with efficacy of 95% protection against COVID-19 infection. Several other vaccines are at different...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156907/ https://www.ncbi.nlm.nih.gov/pubmed/34075362 http://dx.doi.org/10.1016/j.euros.2021.05.007 |
_version_ | 1783699559505985536 |
---|---|
author | Rodriguez Socarrás, Moises Gómez Rivas, Juan Teoh, Jeremy Yuen-Chun Puente, Javier Moschini, Marco Moreno-Sierra, Jesús |
author_facet | Rodriguez Socarrás, Moises Gómez Rivas, Juan Teoh, Jeremy Yuen-Chun Puente, Javier Moschini, Marco Moreno-Sierra, Jesús |
author_sort | Rodriguez Socarrás, Moises |
collection | PubMed |
description | As of April 13, 2021, 137 million cases of COVID-19 and 2.95 million deaths have been reported worldwide. On December 21, 2020, the Pfizer-BioNTech vaccine was approved for use in the European Union, with efficacy of 95% protection against COVID-19 infection. Several other vaccines are at different stages of assessment by the European Medicines Agency. In addition to the elderly, oncology patients are a vulnerable population in which COVID-19 infection may be more severe. However, owing to the design of the initial studies, evidence on the safety and efficacy of vaccination against SARS-CoV-2 in these patients is scarce and recommendations are based on the opinion of associations, stakeholders, and experts via extrapolation of information and experience for other vaccines, especially influenza vaccines. Despite the limited evidence, the consensus is that SARS-CoV-2 vaccines are safe and vaccination of oncology patients and their close relatives is recommended, although efficacy may be lower in patients with an impaired immune response and the need for additional booster doses is not yet clear. Recommendations include avoiding the use of vaccines based on viral vectors for patients with an impaired immune response, deferring vaccination for immunosuppressed patients or administering the vaccine before immunosuppression, and avoiding chemotherapy receipt between the two doses of a vaccine or on the same day that the vaccine is administered. These recommendations can be extrapolated to urology patients and although evidence is lacking, there should not be greater interference with SARS-CoV-2 vaccines from androgen deprivation therapy or intravesical bacillus Calmette-Guérin. However, large studies to provide strong evidence for uro-oncology patients are needed. PATIENT SUMMARY: We looked at the effects of COVID-19 vaccination for patients with urological cancers. The consensus is that the vaccines are safe, and vaccination of cancer patients and their close relatives is recommended. |
format | Online Article Text |
id | pubmed-8156907 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81569072021-05-28 The Uro-oncology Patient and Vaccination Against SARS-CoV-2 Rodriguez Socarrás, Moises Gómez Rivas, Juan Teoh, Jeremy Yuen-Chun Puente, Javier Moschini, Marco Moreno-Sierra, Jesús Eur Urol Open Sci Brief Correspondence As of April 13, 2021, 137 million cases of COVID-19 and 2.95 million deaths have been reported worldwide. On December 21, 2020, the Pfizer-BioNTech vaccine was approved for use in the European Union, with efficacy of 95% protection against COVID-19 infection. Several other vaccines are at different stages of assessment by the European Medicines Agency. In addition to the elderly, oncology patients are a vulnerable population in which COVID-19 infection may be more severe. However, owing to the design of the initial studies, evidence on the safety and efficacy of vaccination against SARS-CoV-2 in these patients is scarce and recommendations are based on the opinion of associations, stakeholders, and experts via extrapolation of information and experience for other vaccines, especially influenza vaccines. Despite the limited evidence, the consensus is that SARS-CoV-2 vaccines are safe and vaccination of oncology patients and their close relatives is recommended, although efficacy may be lower in patients with an impaired immune response and the need for additional booster doses is not yet clear. Recommendations include avoiding the use of vaccines based on viral vectors for patients with an impaired immune response, deferring vaccination for immunosuppressed patients or administering the vaccine before immunosuppression, and avoiding chemotherapy receipt between the two doses of a vaccine or on the same day that the vaccine is administered. These recommendations can be extrapolated to urology patients and although evidence is lacking, there should not be greater interference with SARS-CoV-2 vaccines from androgen deprivation therapy or intravesical bacillus Calmette-Guérin. However, large studies to provide strong evidence for uro-oncology patients are needed. PATIENT SUMMARY: We looked at the effects of COVID-19 vaccination for patients with urological cancers. The consensus is that the vaccines are safe, and vaccination of cancer patients and their close relatives is recommended. Elsevier 2021-05-27 /pmc/articles/PMC8156907/ /pubmed/34075362 http://dx.doi.org/10.1016/j.euros.2021.05.007 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Brief Correspondence Rodriguez Socarrás, Moises Gómez Rivas, Juan Teoh, Jeremy Yuen-Chun Puente, Javier Moschini, Marco Moreno-Sierra, Jesús The Uro-oncology Patient and Vaccination Against SARS-CoV-2 |
title | The Uro-oncology Patient and Vaccination Against SARS-CoV-2 |
title_full | The Uro-oncology Patient and Vaccination Against SARS-CoV-2 |
title_fullStr | The Uro-oncology Patient and Vaccination Against SARS-CoV-2 |
title_full_unstemmed | The Uro-oncology Patient and Vaccination Against SARS-CoV-2 |
title_short | The Uro-oncology Patient and Vaccination Against SARS-CoV-2 |
title_sort | uro-oncology patient and vaccination against sars-cov-2 |
topic | Brief Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156907/ https://www.ncbi.nlm.nih.gov/pubmed/34075362 http://dx.doi.org/10.1016/j.euros.2021.05.007 |
work_keys_str_mv | AT rodriguezsocarrasmoises theurooncologypatientandvaccinationagainstsarscov2 AT gomezrivasjuan theurooncologypatientandvaccinationagainstsarscov2 AT teohjeremyyuenchun theurooncologypatientandvaccinationagainstsarscov2 AT puentejavier theurooncologypatientandvaccinationagainstsarscov2 AT moschinimarco theurooncologypatientandvaccinationagainstsarscov2 AT morenosierrajesus theurooncologypatientandvaccinationagainstsarscov2 AT rodriguezsocarrasmoises urooncologypatientandvaccinationagainstsarscov2 AT gomezrivasjuan urooncologypatientandvaccinationagainstsarscov2 AT teohjeremyyuenchun urooncologypatientandvaccinationagainstsarscov2 AT puentejavier urooncologypatientandvaccinationagainstsarscov2 AT moschinimarco urooncologypatientandvaccinationagainstsarscov2 AT morenosierrajesus urooncologypatientandvaccinationagainstsarscov2 |